Kooij Louise Frederika reported option exercise involving 60,000 derivative units of NewAmsterdam Pharma Co N.V. at $0.00 for $0 on May 26, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Accounting Officer
Chief Accounting Officer
Filed May 27, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
60,000Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
80,015Direct
Trade date
May 26, 2026Option exercise
Filed
May 27, 2026, 4:30 PM ET1-day reporting delay
Accession
0001193125-26-241983Code M · Transaction 90193
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 26, 2026Sell65,000$35.69−$2,319,850Trade 90192
May 26, 2026Option exercise5,000$0.00$0Trade 90194
May 26, 2026Option exercise60,000$10.00$600,000Trade 90190
May 26, 2026Option exercise5,000$10.90$54,500Trade 90191
5 transaction rows in this filing. Joint filers share the same rows.

NAMS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NAMS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −19%1w ago −7.8%1d ago −3.1%
Returns since7d −12%30d −9.1%90d −24%180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.12 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F2: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. F3: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. F4: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.